Approval of Un-audited financial results along with the Limited Review Report for the quarter ended 31.12.2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Arunjyoti Bio Ventures approved its Q3 FY26 (Oct-Dec 2025) unaudited financial results on 03 February 2026. Revenue from operations rose to ₹646.82 lakhs from ₹533.65 lakhs in the previous quarter, and the company swung to a small net profit of ₹4.87 lakhs compared to losses of ₹122.73 lakhs in Q2 FY26 and ₹88.76 lakhs in Q3 FY25. On a nine-month basis, revenue declined ~9.2% YoY to ₹2,051.71 lakhs, though net profit improved to ₹86.48 lakhs (from ₹74.90 lakhs). The auditor (PKF Sridhar & Santhanam LLP) issued an unmodified review report but included an emphasis of matter on restated comparatives related to a deferred tax correction, and noted that prior periods were reviewed by a predecessor auditor, indicating a recent auditor change.
The sequential turnaround to profit is a positive signal, but the 9-month revenue contraction and the restatement of prior figures (along with a change in auditor) may raise governance and consistency concerns for shareholders. Investors should watch whether the Q3 recovery sustains and whether revenue growth resumes in the coming quarters.